Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

• Published in: Journal of clinical pharmacology Vol. 62; no. 4; pp. 505 - 519
• Main Authors: Wang, Ellen Q., Le, Vu, Winton, Jennifer A., Tripathy, Sakambari, Raje, Sangeeta, Wang, Lisy, Dowty, Martin E., Malhotra, Bimal K.
• Format: Journal Article
• Language: English
• Published: England 01.04.2022
• Subjects: abrocitinib; active moiety; Area Under Curve; atopic dermatitis; Dermatitis, Atopic - drug therapy; Female; Humans; Janus Kinase Inhibitors - adverse effects; Janus Kinase Inhibitors - pharmacokinetics; Male; pharmacokinetics; Pyrimidines - adverse effects; Pyrimidines - pharmacokinetics; renal impairment; Renal Insufficiency - metabolism; Sulfonamides - adverse effects; Sulfonamides - pharmacokinetics; pharmacokinetics; atopic dermatitis; active moiety; abrocitinib; renal impairment

Abrocitinib, an oral once‐daily Janus kinase 1 selective inhibitor, is under development for the treatment of atopic dermatitis. This phase 1, nonrandomized, open‐label, single‐dose study (NCT03660241) investigated the effect of renal impairment on the pharmacokinetics, safety, and tolerability of a...